Clopidogrel Bisulphate
Brand Formulations & Prices
41 brands sorted by unit price
Flexiclot
Clopigel
Anplat
Clodogrel
Clopirel
Dogrel
Lirel
Myoclop
APT
Antiplet
Clopidol
Loplate
Anlet
Clocard
Clotinil
Carceva
Cidogrel
Clogfree
Clognil
Clogrel
Clopilet
Cloplet
Dclot
Dorel
Livocard
Lopirel
Navix
Noclog
Odrel
Pidogrel
Pladex
Plagrin
Plator
Preclot
Replet
SB-Clopido
Silclog
Anclog
Clont
Clorel
Clopid
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAcute Coronary Syndrome (ACS)
: Anclog tablet is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)]. It is indicated to reduce the rate of myocardial
... Read more
Acute Coronary Syndrome (ACS)
: Anclog tablet is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)]. It is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI).
Recent MI, recent Stroke, or established Peripheral Arterial Disease
: In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke Anclog tablet is indicated to reduce the rate of MI and stroke.
Acute Coronary Syndrome
: In patients who need an antiplatelet effect within hours, initiate clopidogrel with a single 300 mg (4 tablets) oral loading dose and then continue at 75 mg once daily. Initiating it without a loading dose will delay establishment of an antiplatelet effect by several days.
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
: 75 mg once daily orally without a loading dose.
It is given orally with or without food.
Clopidogrel is contraindicated in the following conditions: Hypersensitivity to the drug substance or any component of the product. Active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Anclog is generally well tolerated drug.
Common side effects
: Bleeding, Diarrhoea, gastrointestinal discomfort, haemorrhage, Skin reactions.
Rare side effects
: Acquired haemophilia, anaemia, angioedema, arthralgia, arthritis, bone marrow disorders.
As it is a prodrug, so metabolism to its active metabolite is impaired by genetic variations in CYP2C19 (poor metabolizer) and by the drugs that inhibit CYP2C19 such as Omeprazole and Esomeprazole. Concomitant use with these drugs and in CYP2C19 poor metaboliser may reduce the antiplatelet activity of Anclog.
As it inhibits platelet aggregation for the lifetime of the platelet (7-10 days), risk of bleeding may increase. To restore hemostasis, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.
Discontinuation of Anclog increases the risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. Resume Anclog as soon as hemostasis is achieved.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported that requires urgent treatment including plasmapheresis (plasma exchange).
Hypersensitivity including rash, angioedema or hematologic reaction has been reported in patients receiving clopidogrel or history of hypersensitivity to other thienopyridines.
Clopidogrel is a prodrug. It inhibits platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses. Repeated doses of 75 mg per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7.